Relationship of Microalbuminuria with Ischemic Heart Disease in Non-Diabetic Subjects
Relationship of Microalbuminuria with Ischemic Heart Disease
DOI:
https://doi.org/10.70284/njirm.v5i3.733Keywords:
Ischemic Heart Disease; Cardiovascular disease; Microalbuminuria; High Density Lipoprotein; Low Density LipoproteinAbstract
Background and Objective: Microalbuminuria is a well accepted marker for micro and macrovascular damage in patients with diabetes mellitus. There is growing evidence that microalbuminuria is an important risk indicator for development of ischemic heart disease. This study was conducted to establish a relationship between microalbuminuria and ischemic heart disease in non-diabetic subjects. Methodology: Fifty randomly selected non-diabetic patients with ischemic heart disease who fulfilled the criteria for the study were evaluated for traditional risk factors and microalbuminuria. Results: Microalbuminuria was detected in 36 (72%) patients with Ischemic Heart Disease (p<0.05). 77% patients with infarct pattern on ECG and 22% patients with ischemia pattern on ECG had microalbuminuria. Majority of patients had microalbuminuria levels between 30-100 mg/day (41% males and 64% females). 72.72% of female patients had microalbuminuria (MA) compared to 71.79% of the male patients. 71.79% of hypertensive patients had microalbuminuria compared to 72.72% of normotensive patients. 79.17% of smokers with microalbuminuria presented with myocardial infarction compared to 62.5% of non-smokers with microalbuminuria. MA level is also associated with ECG (LVH, QTc prolongation) and 2D ECHO findings. Conclusion: Our patients with ischemic heart disease had a significantly positive association with microalbuminuria. Hence, microalbuminuria can be regarded as an additional risk factor for ischemic heart disease. [Suthar N et al NJIRM 2014; 5(3) :51-56
References
2. von Eckardstein A. Is there a need for novel cardiovascular risk factors? Nephrology Dialysis Transplantation 2004;19:761-5.
3. Bennett PH, Haffner S, Kasiske BL, et al. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. American journal of kidney diseases : the official journal of the National Kidney Foundation 1995;25:107-12.
4. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982;1:1430-2.
5. Diercks GF, van Boven AJ, Hillege HL, et al. Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large non-diabetic population. The PREVEND (Prevention of REnal and Vascular ENdstage Disease) study. European heart journal 2000;21:1922-7.
6. de Bruyne MC, Kors JA, Hoes AW, et al. Both decreased and increased heart rate variability on the standard 10-second electrocardiogram predict cardiac mortality in the elderly the rotterdam study. American journal of epidemiology 1999;150:1282-8.
7. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA : the journal of the American Medical Association 2003;290:898-904.
8. Singh RB, Sharma JP, Rastogi V, et al. Prevalence of coronary artery disease and coronary risk factors in rural and urban populations of north India. European heart journal 1997;18:1728-35.
9. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. The New England journal of medicine 2000;342:145-53.
10. Pedrinelli R, Dell'omo G, Catapano G, et al. Microalbuminuria and endothelial dysfunction in essential hypertension. The Lancet 1994;344:14-8.
11. Jerums G, MacIsaac RJ. Treatment of microalbuminuria in patients with type 2 diabetes mellitus. Treatments in endocrinology 2002;1:163-73.
12. Geluk CA, Asselbergs FW, Hillege HL, et al. Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. European heart journal 2005;26:1314-20.
13. Akintunde AA, Familoni OB, Akinwusi PO, Opadijo OG. Relationship between left ventricular geometric pattern and systolic and diastolic function in treated Nigerian hypertensives: cardiovascular topics. Cardiovascular journal of Africa 2010;21:21-5.
14. Redon J, Williams B. Microalbuminuria in essential hypertension: redefining the threshold. Journal of hypertension 2002;20:353-5.
